Trial Profile
A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms NB001
- 27 May 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2017 New trial record